Jasper Therapeutics
在场
高管
查看带有其 18 名主要高管的组织结构图
Jasper Therapeutics 搜索最多的简介
高管在Jasper Therapeutics变化
- Thomas Wiggans已作为Chairman of the Board加入公司 (新闻发布的2023十一月1号).
- Bill Lis, Chairman of the Board, 已经离开公司 (新闻发布的2023十一月1号).
- Jeet Mahal 曾任 Chief Operating and Financial Officer, 现任 Chief Operating Officer (新闻发布的2023九月26号).
创建提醒
跟踪 Jasper Therapeutics 的高管变动
生物技术
Jasper Therapeutics 拥有 2,297 家竞争者，其中包括 Lonza (瑞士)、Eurofins (卢森堡) 和 Adaptive Phage Therapeutics (美国(美洲))。
Popular M&A news in 生物技术
- Grey Wolf Therapeutics 刚刚宣布为 50 筹款数百万美元。 (公布2024五月25号).
- AbbVie 已收购 Landos Biopharma (公布2024五月25号).
- AltruBio 刚刚宣布为 225 筹款数百万美元。 (公布2024五月24号).
生物技术 行业的其他推荐联系人
消息
Jasper Therapeutics 的最新新闻稿
- News Releases | Jasper Therapeutics, Inc
- Jasper Therapeutics and Aruvant Announce Research Collaboration to Study JSP191, an Antibody-Based Conditioning Agent, with ARU-1801, a Novel Gene Therapy for the Treatment of Sickle Cell Disease
- Jasper Therapeutics Announces Orphan Drug and Rare Pediatric Disease Designations for JSP191 for Conditioning Treatment Prior to Stem Cell Transplant | Business Wire
- Jasper Therapeutics to Host Webcast to Review Updated 90-day Data from Phase 1 Clinical Trial of JSP191 That is Being Presented at 2021 ASCO Virtual Annual Meeting | Business Wire
- Jasper Therapeutics Announces New Clinical Trial with the National Institute of Allergy and Infectious Diseases to Evaluate JSP191 in Chronic Granulomatous Disease | Business Wire
- Jasper Therapeutics Announces Updated 90-day Data from Phase 1 Clinical Trial of JSP191 as Targeted Stem Cell Conditioning Agent in Older Patients with Myelodysplastic Syndromes or Acute Myeloid Leukemia Undergoing Hematopoietic Cell Transplantation | Bus
- Jasper Therapeutics and Amplitude Healthcare Acquisition Corporation Announce Merger to Create a Publicly Listed Leading Biotechnology Company in Hematopoietic Stem Cell Transplantation | Business Wire
- Jasper Therapeutics Announces Launch of New Clinical Trial with National Heart, Lung, and Blood Institute to Evaluate JSP191 in Sickle Cell Disease | Business Wire
- Jasper Therapeutics Announces Positive Data from Phase 1 Clinical Trial of JSP191 as Targeted Stem Cell Conditioning Agent in Patients with Myelodysplastic Syndromes or Acute Myeloid Leukemia Undergoing Hematopoietic Cell Transplantation | Business Wire
- Jasper Therapeutics and Graphite Bio Announce Collaboration to Evaluate JSP191 as Conditioning Regimen for Novel Gene Replacement Therapy in Patients with XSCID | Business Wire
- View more press releases Close
通过电子邮件
